BChE
Butyrylcholinesterase (BChE, EC 3.1.1.8) is a cholinesterase family enzyme that hydrolyzes a broad range of choline esters and other ester-containing substrates, contributing to cholinergic regulation as well as xenobiotic detoxification processes[1][2]. BChE is widely distributed in human tissues and plasma, where it participates in cholinergic transmission, ester metabolism, and the neutralization of toxic compounds including organophosphates and carbamates[1]. Mechanistically, BChE functions as a hydrolytic enzyme that can buffer acetylcholine metabolism when acetylcholinesterase (AChE) activity is reduced, thereby influencing cholinergic homeostasis[2]. In disease contexts, increasing evidence links BChE to neurodegenerative disorders, particularly Alzheimer’s disease (AD), where BChE activity and expression become more prominent during disease progression and are associated with late-stage cholinergic dysfunction[3][4]. Experimental studies therefore consider BChE an important therapeutic target and biomarker candidate for AD-related research[3][4]. Compared with the closely related isoform AChE, which primarily terminates synaptic acetylcholine signaling, BChE exhibits broader substrate specificity, distinct tissue distribution, and a stronger role in drug metabolism, detoxification, and non-neuronal physiological processes[1][2]. For experimental applications, selective BChE inhibitors are widely used to investigate cholinergic mechanisms and have been developed as pharmacological tools for evaluating therapeutic strategies in neurodegenerative disease models, with high selectivity over AChE considered a key design objective[3][4].
References:
- [1]. Hajimohammadi S, et al. New views on physiological functions and regulation of butyrylcholinesterase and potential therapeutic interventions. Front Mol Biosci. 2025 Jun 19;12:1625318. [Content Brief]
- [2]. Jovičić SM. Enzyme ChE, et al. Enzyme ChE, cholinergic therapy and molecular docking: Significant considerations and future perspectives. Int J Immunopathol Pharmacol. 2024 Jan-Dec;38:3946320241289013. [Content Brief]
- [3]. Brus B, et al. Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor. J Med Chem. 2014 Oct 9;57(19):8167-79. [Content Brief]
- [4]. Zhou Y, et al. Discovery of Selective Butyrylcholinesterase (BChE) Inhibitors through a Combination of Computational Studies and Biological Evaluations. Molecules. 2019 Nov 20;24(23):4217. [Content Brief]
All Product Categories
-
BChE Related Products (220)
Related Products (220)
-
Desoxypeganine
0 ImagesDesoxypeganine (Deoxypeganine), an alkaloid, is a potent and orally active cholinesterase (BChE and AChE) and selective MAO-A inhibitor, with IC50 values of 2, 17, and 2 μM, respectively. Desoxypeganine can be used for alcohol abuse research.
-
Multitarget AD-IN-5
0 ImagesCat. No.: HY-181041Multitarget AD-IN-5 (Compound 20), 9-Aminoacridine (HY-B1422) derivative, is a neuroprotective agent. Multitarget AD-IN-5 shows IC50 values of 0.614, 0.448, 3.73 and 1.55 μM for hAChE, hBChE, hMAO-A and hMAO-B. Multitarget AD-IN-5 can reduce length and diameter of Aβ42 fibers, and decrease the number of fibers per unit area. Multitarget AD-IN-5 can be used for research of Alzheimer's disease.
-
BChE-IN-48
0 ImagesCat. No.: HY-180146BChE-IN-48 (Compound 12a) is a BChE inhibitor that can cross the blood-brain barrier with IC50 values for eqBChE and huBChE of 1.3 and 0.95 μM respectively. BChE-IN-48 exhibits an IC50 value for eeAChE of 8.6 μM. BChE-IN-48 exhibits significant neuroprotective activity in cell damage and significantly improves cognitive impairment in mouse models. BChE-IN-48 can be used for research on Alzheimer's disease.
-
AChE/BChE-IN-12
0 ImagesCat. No.: HY-149211AChE/BChE-IN-12 (compound 10b), a 3,5-dimethoxy analogue, is a potent AChE, BChE, and β-secretase-1 (BACE-1) inhibitor, with IC50 values of 2.57, 3.26, and 10.65 μM, respectively. AChE/BChE-IN-12 crosses the blood-brain barrier via passive diffusion and inhibits the self-aggregation of amyloid-β monomers. AChE/BChE-IN-12 can be used for Alzheimer’s disease (AD) research.
-
Bisnorcymserine
0 ImagesCat. No.: HY-121191CAS No.: 219920-81-7Synonyms: N1,N8-Bisnorcymserine; (-)-Bisnorcymserine
-
BChE-IN-12
0 ImagesCat. No.: HY-N10489CAS No.: 136966-86-4BChE-IN-12 (compound 12) is a potent butyrylcholinesterase (BChE) non-competitive inhibitor with an IC50 value of 2.3 μM. BChE-IN-12 can be isolated from Bletilla striata. BChE-IN-12 can be used for the research of Alzheimer's disease (AD).
-
hCA I-IN-4
0 ImagesCat. No.: HY-169962CAS No.: 3054159-56-4hCA I-IN-4 (Compound 14) is the inhibitor for carbonic anhydrase and cholinesterase, that inhibits hCA I, hCA II, AChE, and BChE with Ki of 29.94 nM, 17.72 nM, 21.21 nM, and 7.65 nMrespectively. hCA I-IN-4 exhibits cytotoxicity in BT-549 with IC50 of 16.59 μM.
-
hAChE/hBACE-1-IN-4
0 ImagesCat. No.: HY-161512CAS No.: 229476-71-5hAChE/hBACE-1-IN-4 (compound AK-2) is a quinazoline derivative. hAChE/hBACE-1-IN-4 shows significant inhibitory activity against hAChE and hBACE-1 enzymes (hAChE, IC50=0.283 μM; hBACE-1, IC50=0.231 μM). hAChE/hBACE-1-IN-4 has the potential to inhibit Aβ aggregation. hAChE/hBACE-1-IN-4 has non-neurotoxicity , blood-brain barrier permeability and oral activity. hAChE/hBACE-1-IN-4 can be used in Alzheimer's disease research.
-
Difeterol
0 ImagesCat. No.: HY-118729CAS No.: 14587-50-9Difeterol is an antihistamine agent and histamine-1 receptor antagonist. Difeterol inhibits BChE. Difeterol can be used in the research of Alzheimer's disease.
-
CUR-IPA
0 ImagesCat. No.: HY-172219CUR-IPA is a cholinesterase inhibitor, with IC50 of 5.99, 59.30, and 60.66 μM for eAChE (electric eel), hAChE (human), and hBChE (human), respectively. CUR-IPA can scavenge free radicals and has antioxidant activity. CUR-IPA can be used in the research of cognitive dysfunction.
-
AChE/BChE-IN-25
0 ImagesCat. No.: HY-168731AChE/BChE-IN-25 (Compound 6e) is the orally active inhibitor for hAChE and eqBChE with IC50 of 7.9 nM and 0.79 nM. AChE/BChE-IN-25 exhibits antioxidant activity, that scavenges free radical with IC50 of 22.91 μM. AChE/BChE-IN-25 exhibits neuroprotective effects by reducing mitochondrial and cellular oxidative stress in the Drosophila Alzheimer's disease model. AChE/BChE-IN-25 ameliorates Scopolamine (HY-N0296)-induced spatial and cognitive memory impairment in mouse model.
-
AChE/BChE-IN-27
0 ImagesCat. No.: HY-174399AChE/BChE-IN-27 is a blood-brain barrier-permeable mixed inhibitor (Pe = 4.12) of AChE and BChE, with IC50 values of 3.72 μM and 9.65 μM, respectively. AChE/BChE-IN-27 has potent antioxidant activity with an IC50 value of 6.32 μM in the DPPH (HY-112053) assay and also exhibits potent in vitro antioxidant activity. AChE/BChE-IN-27 exhibits metal chelating properties. AChE/BChE-IN-27 has neuroprotective potential against oxidative stress. AChE/BChE-IN-27 significantly reduces intracellular reactive oxygen species (ROS). In in vivo experiments, AChE/BChE-IN-27 effectively restored AChE and BChE levels, improved cognition, and can be used for Alzheimer's disease (AD).
-
BuChE-IN-12
0 ImagesCat. No.: HY-162671CAS No.: 1363947-94-7BuChE-IN-12 is a selective BuChE inhibitor (IC50=0.52 µM) that acts via affecting CAS and PAS sites and has potential effects against oxidative stress. BuChE-IN-12 can be used in the study of Alzheimer's disease.
-
AChE-IN-114
0 ImagesCat. No.: HY-185347CAS No.: 2365405-51-0
-
S21-1011
0 ImagesCat. No.: HY-161643CAS No.: 2671859-87-1S21-1011 is a selective inhibitor for butyrylcholinesterase (BChE), with IC50 of 0.059 and 0.162 μM, for eqBChE and hBChE, respectively. S21-1011 exhibits good blood-brain barrier (BBB) permeability and good pharmacokinetic characters. S21-1011 exhibits anti-inflammatory activity through activation of keap1-Nrf2-ARE pathway (EC50 is 23.48 μM for antioxidant element ARE activation), ameliorates cognitive impairment in murine Alzheimer’s disease model.
-
AChE/BuChE-IN-8
0 ImagesCat. No.: HY-181503AChE/BuChE-IN-8 is a dual AChE and BuChE inhibitor, with an AChE IC50 of 1.18 μM, a human AChE Ki of 1.2 μM, and a BuChE IC50 of 2.34 μM. AChE/BuChE-IN-8 acts as an antiproliferative agent and antioxidant, exerts antiproliferative effects on colon cancer cells, scavenges free radicals, and exhibits reducing power. AChE/BuChE-IN-8 can be used in the research of Alzheimer's disease and colorectal adenocarcinoma.
